Rapid Testing for COVID-19
Randox has developed a rapid test for COVID-19 (SARS-CoV-2), the new strain of coronavirus. The only test in the world that can identify the lethal strain and differentiate between other non-lethal variants with the same symptoms.
Our revolutionary test will identify and confirm the presence of COVID-19, allowing for the correct and appropriate course of action to be taken. Importantly, our test will simultaneously differentiate between 9 other respiratory viruses that show similar symptoms providing fast and accurate diagnosis of these other strains if they are present.
The new test utilises Randox Biochip Technology, reporting 540 results in less than 5 hours on the Evidence Investigator, a semi-automated analyser that is capable of processing 54 patient samples simultaneously.
Vivalytic consolidates the full molecular workflow into a small benchtop platform, capable of extraction, PCR amplification and detection. Randox multiplex Biochip Technology powers Vivalytic enabling multiple results from one patient sample.
The Randox Discovery is an exciting and revolutionary molecular diagnostic testing technology. The fully automated benchtop multiplex analyser consolidates the normal workload of multiple laboratory rooms into one compact benchtop platform.